Compare MKS Instruments (MKSI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MKS Instruments vs Summit Therapeutics Inc — how do they compare? MKS Instruments trades at $268.04 (market cap $17.95B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: MKS Instruments is the larger of the two by market cap, and MKS Instruments pays a 0.38% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MKSI | SMMT | |
|---|---|---|
Market Cap | $17.95B | $13.79B |
Sector | Technology | Health |
52-Week High | $444.80 | $26.38 |
52-Week Low | $110.60 | $12.43 |
Enterprise Value | $21.53B | $13.11B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MKS Instruments
MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.
Read more on MKSI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
